Analysis on the research progress and prospect of novel coronavirus vaccine

Nan Yang

doi:10.1117/12.2669352

24 March 2023 Analysis on the research progress and prospect of novel coronavirus vaccine

Nan Yang

Proceedings Volume 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022); 126116L (2023) https://doi.org/10.1117/12.2669352
Event: International Conference on Biological Engineering and Medical Science (ICBioMed2022), 2022, Oxford, United Kingdom

Abstract

The novel coronavirus disease 2019 (2019-NCOV), caused by the novel coronavirus (2019-NCOV), is raging around the world and has become an important global public health problem threatening human health. Since the outbreak in 2019, as of early October 2022, the cumulative confirmed cases of COVID-19 have reached 615,689,999 and the cumulative death cases have reached 6,526,739. The top five countries with the most confirmed cases are the United States, India, France, Brazil, and Germany. Currently, many people worldwide are still at risk of morbidity and mortality from SARS-CoV-2 and COVID-19. In the absence of specific drugs, vaccination is undoubtedly the most effective way to block the spread of the virus. As of July 2022, 16 vaccines have been approved for marketing or emergency use, and more than 250 vaccines are under development, among which 167 are in phase III clinical trials. By September 2022, nine vaccines had been conditionally marketed or approved for emergency use in China. This paper mainly reviews the specific characteristics and research and development status of various COVID-19 vaccines, as well as their safety and effectiveness. In addition, the future trends and challenges of vaccine research and development are analyzed based on the current situation.

Citation Download Citation

Nan Yang "Analysis on the research progress and prospect of novel coronavirus vaccine", Proc. SPIE 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022), 126116L (24 March 2023); https://doi.org/10.1117/12.2669352

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available